Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper
Portfolio Pulse from Benzinga Newsdesk
Mainz Biomed NV (NASDAQ:MYNZ) announced initial results from its colorectal cancer screening campaign through its BGM partnership with Zöeller-Kipper GmbH. In April 2023, Zöeller-Kipper selected ColoAlert®, Mainz Biomed's screening test for CRC, for its corporate health program.
May 24, 2023 | 7:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mainz Biomed's partnership with Zöeller-Kipper for its colorectal cancer screening campaign may boost the company's reputation and sales.
The partnership with Zöeller-Kipper, a company with over 2,500 employees, showcases Mainz Biomed's CRC screening test, ColoAlert®, as a reliable and effective product. This partnership may lead to increased sales and a positive impact on MYNZ's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100